Anticipated $-0.89 EPS for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) on June, 15

May 17, 2018 - By Cristopher Snider

Earnings report for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is awaited on June, 15., Zacks reports. Analysts forecast $-0.89 earnings per share. That’s $0.85 up or 48.85 % from 2017’s earnings of $-1.74. After $-0.75 EPS report previous quarter, Wall Street now sees 18.67 % negative EPS growth of Biohaven Pharmaceutical Holding Company Ltd.. BHVN reached $29.95 during the last trading session after $0.18 change.Currently Biohaven Pharmaceutical Holding Company Ltd. is after 0.00% change in last May 17, 2017. BHVN has 453,190 shares volume. BHVN underperformed the S&P 500 by 11.55%.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders.The firm is valued at $1.16 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia.Currently it has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

For more Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news published briefly go to: Seekingalpha.com, Streetinsider.com, Prnewswire.com, Prnewswire.com or Seekingalpha.com. The titles are as follows: “Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant” published on April 23, 2018, “Biohaven (BHVN) to Present Additional Phase 3 Rimegepant Data at AAN 2018 on April 22nd” on April 19, 2018, “Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients …” with a publish date: May 09, 2018, “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” and the last “Biohaven Pharma announces key milestones for 2018” with publication date: May 15, 2018.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.